Want to know if this job is worth applying to?
Wien, Österreich
Hybrid
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.
The Opportunity:
The Market Access Director, Austria is responsible for defining and executing the country market access strategy to ensure timely, sustainable patient access to innovative oncology therapies. This role shapes reimbursement and access strategy, drives value demonstration, and leads engagement with key external stakeholders including payers, HTA bodies, and health authorities.
This position will partner with regulatory, commercial and medical affairs teams to deliver launch activities by providing access insights, developing evidence-based HTA, Pricing & Reimbursement dossiers and tools, engaging with market access and public affairs stakeholders as well as driving pricing strategy activities, and lead the activities to deliver access results supporting the overall success of the product launches aligned with patient needs.
Required Skills, Experience and Education:
Lead Market Access & Reimbursement: Develop and implement strategies to support access and pricing decisions for RevMed portfolio and launches within the Austria healthcare system.
HTA & Pricing Filings: Lead preparation and submission of value dossiers, benefit assessments and pricing negotiations with statutory health insurance decision makers.
Partner with regional and local Medical Affairs and Marketing team to translate clinical and economic evidence into compelling value communications tailored for Austria payers.
Build and maintain strong relationships with key external stakeholders (payers, HTA authorities, policy influencers). Representation of Revolution Medicines at local trade associations for market access subjects.
Work with Midsized Markets and Regional Market Access teams to align local access strategy with broader European and corporate objectives, especially in terms of aligning the European regulatory strategy and execution with local value dossier submission and pricing negotiation strategy.
Provide early market access input to regional and European clinical development and medical teams.
Lead negotiation with all levels of national payers.
Develop innovative pricing and value based contracting models to optimize the acceleration of reimbursement approvals.
Policy Monitoring: Monitor health policy developments, HTA processes and local reimbursement environments to inform strategy.
Represent Market Access in Austria Leadership Team meetings and contribute to overall business strategy.
Drive access and value related projects such as landscape assessments, payer market research, payer advisory boards and general guidance on local strategies.
Development of outreach and engagement plan for key payers creating and maintaining a strong network.
Early access planning of new products and indications, drive launch readiness for multiple oncology assets (portfolio responsibility).
Influence European and Midsised Markets access strategy based on local payer insights from a leadership position.
Travel nationally and internationally.
Preferred Skills:
Advanced degree (e.g., Life Sciences, Pharmacy, Health Economics, Public Health).
A minimum of 10 years’ experience in market access, pricing, reimbursement or health economics (pharma/biotech) in Austria.
Proven value and benefit assessment experience, with deep understanding of Austria payer decision-making.
Demonstrated success and experience supporting oncology product pre-launch, launch and post launch in Austria.
Demonstrated success in negotiating pricing and reimbursement conditions with public administrations and health authorities.
Strong stakeholder management and ability to collaborate with internal and external partners.
Excellent interpersonal and communication skills.
Scientific and solution-orientated mindset and capability to move and execute in a rapidly changing, ambiguous environment.
Strong understanding of local healthcare systems, customer dynamics, and reimbursement environments.
Experience in a biotech and/or in a build-out.
High capacity of social competence for teamwork, coaching and situational leadership.
Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact privacy@revmed.com.
#LI-Hybrid #LI-LO1
We are aware of recent recruitment scams in which individuals or organizations falsely represent themselves as being affiliated with Revolution Medicines. These scams may appear as false job advertisements or unsolicited contacts through communication or chat platforms, email, phone, or text message.
Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process. All legitimate communication from Revolution Medicines will come from an official @revmed.com email address.
If you believe you’ve been contacted by someone impersonating a Revolution Medicines recruiter, please report it to careers@revmed.com so we can share these impersonations with our IT team for tracking and awareness.
